Cognition Therapeutics has reported phase 2 data with its Alzheimer's disease candidate, claiming the results show proof-of-concept for the drug, although the study missed its main endpoint. Cognition ...

The browser you are using is no longer supported on this site. It is highly recommended that you use the latest versions of a supported browser in order to receive an optimal viewing experience. The ...